GlassScriptPhysician profile
Abdullah Al Farooque
NPI 1467409961
$4,920.18
in general payments reported to CMS, 2019-2025
36 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $814 · 2021: $925 · 2022: $848 · 2023: $608 · 2024: $353 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,386.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $540.69 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $406.36 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $354.47 | 2019-2023 | Kristalose |
| Amgen INC. | $292.88 | 2019-2023 | Tezspire, Repatha, Otezla |
| Lilly USA, LLC | $288.99 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $210.17 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $182.43 | 2019-2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $179.24 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.44 | 2019-2022 | |
| Esperion Therapeutics, INC. | $96.15 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.22 | 2019-2021 | |
| Amarin Pharma, INC. | $91.21 | 2019-2021 | |
| Straumann USA LLC | $76.97 | 2021 | |
| Mylan Specialty L.P. | $64.41 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57.63 | 2019-2020 | |
| Qorumpartners | $51.44 | 2022 | |
| Madrigal Pharmaceuticals | $49.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Xeris Pharmaceuticals, INC. | $46.58 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $24.32 | 2022 | |
| Redhill Biopharma INC. | $22.75 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.84 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.69 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.70 | 2021 | |
| Dexcom, INC. | $20.26 | 2024 | Dexcom G6 Transmitter |
| Watermark Medical, INC. | $18.99 | 2024 | |
| Hologic Sales and Service, LLC | $18.92 | 2021 | |
| Tactile Systems Technology INC | $18.80 | 2023 | Entre Plus, Flexitouch Plus |
| Novavax INC | $18.43 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Allergan, INC. | $17.19 | 2020 | |
| Linus Health, INC. | $16.86 | 2024 | Core Cognitive Evaluation |
| Eisai INC. | $14.87 | 2021 | |
| Genentech USA, INC. | $13.29 | 2021 | |
| Sanofi Pasteur INC. | $13.10 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $12.21 | 2021 | |
| Hikma Pharmaceuticals USA | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Farooque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.